

New haematology reimbursements in Belgium

T. Feys

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2018;9(6):245)

SPRYCEL® in Belgium is now also indicated for the treatment of pediatric patients with newly diagnosed Ph + CML in the chronic phase (Ph + CML-CP) or with Ph + CML-CP who are resistant or intolerant to earlier administered medicines including imatinib¹.

In this new indication, SPRYCEL will be eligible for reimbursement from November 1st 2018, if it is administered to a child, with a minimum body weight of 10 kg and capable of swallowing tablets².

The reimbursement can be granted via an electronic request submitted via the eHealth platform. This can only be done by a doctor specialist, recognized in pediatrics and holder of the special professional qualification in pediatric hematology and oncology².

REFERENCES:

1. Sprycel® Summary of Product Characteristics, Bristol Myers Squibb
2. RIZIV/INAMI website

Ariez International BV, Ghent, Belgium.

Please send all correspondence to: T. Feys, MSc, MBA, Ariez international BV, Oude Houtlei 118, 9000 Ghent, Belgium, tel: +32 479 56 78 90, email: t.feys@ariez.com.

Conflict of interest: The author has nothing to disclose and indicates no potential conflict of interest.